GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » Cyclically Adjusted PB Ratio

Neurocrine Biosciences (Neurocrine Biosciences) Cyclically Adjusted PB Ratio : 14.15 (As of Apr. 28, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Neurocrine Biosciences's current share price is $135.99. Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $9.61. Neurocrine Biosciences's Cyclically Adjusted PB Ratio for today is 14.15.

The historical rank and industry rank for Neurocrine Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

NBIX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.62   Med: 15.49   Max: 47.47
Current: 14.16

During the past years, Neurocrine Biosciences's highest Cyclically Adjusted PB Ratio was 47.47. The lowest was 1.62. And the median was 15.49.

NBIX's Cyclically Adjusted PB Ratio is ranked worse than
96.91% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs NBIX: 14.16

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Neurocrine Biosciences's adjusted book value per share data for the three months ended in Dec. 2023 was $22.614. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.61 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Neurocrine Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Neurocrine Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Cyclically Adjusted PB Ratio Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.88 22.21 14.36 15.67 13.72

Neurocrine Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.67 12.48 10.95 12.32 13.72

Competitive Comparison of Neurocrine Biosciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PB Ratio falls into.



Neurocrine Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Neurocrine Biosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=135.99/9.61
=14.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Neurocrine Biosciences's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=22.614/129.4194*129.4194
=22.614

Current CPI (Dec. 2023) = 129.4194.

Neurocrine Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201403 3.257 99.695 4.228
201406 3.120 100.560 4.015
201409 2.948 100.428 3.799
201412 2.729 99.070 3.565
201503 5.678 99.621 7.376
201506 5.445 100.684 6.999
201509 5.204 100.392 6.709
201512 4.920 99.792 6.381
201603 4.770 100.470 6.144
201606 4.392 101.688 5.590
201609 4.048 101.861 5.143
201612 3.624 101.863 4.604
201703 2.824 102.862 3.553
201706 3.914 103.349 4.901
201709 3.928 104.136 4.882
201712 4.191 104.011 5.215
201803 4.055 105.290 4.984
201806 4.175 106.317 5.082
201809 4.935 106.507 5.997
201812 5.295 105.998 6.465
201903 4.484 107.251 5.411
201906 5.284 108.070 6.328
201909 6.239 108.329 7.454
201912 6.902 108.420 8.239
202003 7.546 108.902 8.968
202006 8.918 108.767 10.611
202009 8.611 109.815 10.148
202012 12.045 109.897 14.185
202103 12.758 111.754 14.775
202106 13.522 114.631 15.266
202109 14.198 115.734 15.877
202112 14.478 117.630 15.929
202203 14.566 121.301 15.541
202206 14.889 125.017 15.413
202209 16.073 125.227 16.611
202212 17.697 125.222 18.290
202303 17.277 127.348 17.558
202306 18.986 128.729 19.088
202309 20.388 129.860 20.319
202312 22.614 129.419 22.614

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Neurocrine Biosciences  (NAS:NBIX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Neurocrine Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Executives
Kevin Charles Gorman officer: Sr VP, Business Development 12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter director 9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano officer: Chief Business Dev Officer NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts officer: Chief Medical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke officer: Chief Human Resources Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons director, officer: President and CEO 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt officer: Chief Legal Officer C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia officer: Chief Scientific Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer officer: Chief Corp. Affairs Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet officer: Chief Regulatory Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy officer: Chief Financial Officer C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich officer: Chief Commerical Officer C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith officer: Chief Regulatory Officer 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080